2026-08-06
A video review of nattokinase ("The Internet is Misleading You on this Popular Supplement (Doctor Explains)", https://www.youtube.com/watch?v=qRLiXKRuUCI) argues the clot-dissolving soy-fermentation enzyme is overhyped relative to its evidence: applying a three-level hierarchy — biomarkers, then structural change (arterial plaque), then hard outcomes (heart attacks, strokes, deaths) — the host, explicitly generalizing the framework to any supplement (echoing Evaluating Nutrition & Fitness Evidence), finds a plausible ~5-7 point systolic blood-pressure reduction and a real but double-edged anticoagulant effect (protective against clot-driven events, riskier for bleeding-prone people), but locates the flagship 1,000+-person Chinese plaque-reduction claim in a weak, unreplicated, non-randomized retrospective cohort at very high doses (>10,000 FU) that he calls merely "hypothesis generating," contrasts it with an underpowered but better-designed small pilot RCT (6,000 FU vs. simvastatin) and a null, properly randomized USC trial at a lower 2,000 FU dose, flags wildly inconsistent dosing (2,000-13,000+ FU) as a confound across the whole literature, and notes zero randomized outcome trials exist yet — so, warning that promising preclinical/biomarker data can still flip to net harm once tested rigorously, he personally doesn't take nattokinase and hasn't recommended it to family with arterial plaque, while separately noting natto as a whole fermented food (also containing vitamin K2, isoflavones, protein, fiber) is associated with lower cardiovascular mortality across multiple studies, with a caution for people on warfarin.
2026-08-06
[2026-08-06] A new randomized controlled creatine study reignited debate over whether creatine's lean-mass gains are real muscle or just water weight, per a Physionic video analysis ('Creatine Debunked: No Extra Muscle Gained - Were we Duped?', https://www.youtube.com/watch?v=oMwRo4BB_5I). Its methodological contribution was measuring lean body mass at baseline, again after a 1-week creatine-only 'wash-in' period before any resistance training, and again after 13 weeks of training: creatine alone produced a statistically significant, suspiciously fast lean-body-mass jump within that first week — almost certainly water retention picked up by DEXA rather than muscle — and when that inflated 1-week reading is used as the new baseline instead of the true baseline, creatine's apparent 13-week advantage over placebo disappears, which is the result media coverage seized on as proof creatine doesn't build muscle. Physionic argues this overreaches: the same study's muscle biopsies showed significant increases in individual muscle-fiber cross-sectional size with creatine, and while cell-size growth alone doesn't prove increased contractile (myofibrillar) tissue versus more intracellular water, separate outside research directly measuring contractile proteins like myosin still shows a creatine advantage. He also notes lean/fat-free mass are imprecise muscle proxies (they include bone and connective tissue) and that the study, while adequately powered to detect LBM differences, may not have been powered to detect finer muscle-specific effects. His verdict: the study is valuable for exposing a genuine design flaw in prior creatine research (failure to control for initial water retention before assessing training-driven gains) without overturning creatine's effectiveness for muscle growth — relevant follow-up context for Creatine Supplementation and a good case study for Evaluating Nutrition & Fitness Evidence.
2026-08-06
A retrospective study of over 25,000 people over 11 years, covered by Physionic in "Creatine linked to Cancer Risk - New Study," finds that at the highest creatine-intake quartile (starting around 200-250 mg/day), consumption is inversely associated with cancer incidence — more creatine, less cancer, with a dose-response relationship strengthening further at the top of that quartile — after adjusting for age, sex, weight, blood pressure, and exercise; Physionic frames this as encouraging but weakly protected from confounding, since isolating a single molecule (unlike broad 'effector' categories such as total meat consumption, which the study left unadjusted despite meat being creatine's primary dietary source, or total energy intake) leaves countless correlated factors uncontrolled, so no strong standalone conclusion should be drawn either for or against creatine's cancer risk.